Azitra Graham Number
The Graham Number of Azitra (AZTR) as of Oct 21, 2026 is 2.72 USD. In the previous year, Graham Number was 27.97 USD — a change of -90.27% (lower).
Get this data via API
Financial Data API
Graham Number
2.72USD
YoY
-90.27%
Last updated:
Graham Number of Azitra is 2025 2.72 USD. Graham Number of Azitra was 2024 27.97 USD. It decreases by -90.27% lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Azitra Stock analysis
What does Azitra do? Azitra Inc., based in Branford, Connecticut, is an early-stage biopharmaceutical company focused on developing topical therapies for dermatological conditions. The company utilizes engineered proteins and live biotherapeutic products, leveraging a microbial library of 1,500 bacterial strains and AI-driven screening to create treatments for skin diseases. Its pipeline includes ATR-12 for Netherton syndrome, ATR-04 for papulopustular rash, and ATR-01 for ichthyosis vulgaris, all targeting unmet medical needs in precision dermatology. Listed on June 16, 2023, Azitra operates with a team of 10 employees. Azitra is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Azitra stock
Graham Number of Azitra is 2.72 USD in 2025.
On Eulerpool you can find the complete historical development of Graham Number Azitra since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Azitra
All Key Metrics — Azitra
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth